Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Ehsan Irajizad

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7510-4849; OpenAlex author ID A5013889074. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
60
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 2 papers · 2026: 2 papers

Papers 12

  1. Assessment of impending pancreatic cancer in a cohort of new onset diabetes on basis of biomarker trajectory Co-author DOI 10.64898/2026.08.06.26359908↗
  2. KRAS-driven metabolic reprogramming of enhanced MFSD2A-mediated lysophosphatidylcholine scavenging promotes survival and progression of pancreatic ductal adeno… Co-author DOI 10.64898/2026.10.05.756824↗
  3. Lead time trajectory of blood-based protein biomarkers for detection of pancreatic cancer based on repeat testing. Last author DOI 10.1016/j.canlet.2025.217450↗
  4. Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progress… Co-author DOI 10.1158/1078-0432.ccr-24-2931↗
  5. Contributions of the Microbiome-Derived Metabolome for Risk Assessment and Prognostication of Pancreatic Cancer. Co-author DOI 10.1093/clinchem/hvad186↗
  6. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  7. A Blood-based Metabolite Signature for Personalized Risk Assessment of Pancreatic Cancer. Co-author DOI 10.33696/cancerimmunol.6.095↗
  8. A blood-based metabolomic signature predictive of risk for pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101194↗
  9. Integrated spatial transcriptomics and lipidomics of precursor lesions of pancreatic cancer identifies enrichment of long chain sulfatide biosynthesis as an ea… Co-author DOI 10.1101/2023.08.14.553002↗
  10. CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. Co-author DOI 10.1016/j.molmet.2021.101426↗
  11. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Co-author DOI 10.1053/j.gastro.2020.11.052↗
  12. CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. Co-author DOI 10.1200/po.19.00330↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Johannes Francois Fahrmann · 12 shared papers, 2020–2026 · strength 1.95
  2. Anirban Maitra · 12 shared papers, 2020–2026 · strength 1.95
  3. Samir Hanash · 11 shared papers, 2020–2026 · strength 1.73
  4. Jody V. Vykoukal · 10 shared papers, 2020–2026 · strength 1.60
  5. Jianjun Zhang · 6 shared papers, 2021–2025 · strength 1.06
  6. Ricardo A. Léon-Letelier · 5 shared papers, 2023–2026 · strength 0.94
  7. Michele Yip-Schneider · 5 shared papers, 2021–2025 · strength 0.84
  8. Christian Max Schmidt · 5 shared papers, 2021–2025 · strength 0.83
  9. Yihui Chen · 4 shared papers, 2022–2026 · strength 0.65
  10. Riccardo Ballarò · 3 shared papers, 2024–2026 · strength 0.62
  11. Brian Matthew Wolpin · 4 shared papers, 2021–2026 · strength 0.56
  12. Eugene Jon Koay · 2 shared papers, 2026 · strength 0.44
  13. Florencia M. McAllister · 2 shared papers, 2026 · strength 0.44
  14. Ana Babić · 3 shared papers, 2021–2024 · strength 0.35
  15. Andrea J. Bullock · 3 shared papers, 2021–2024 · strength 0.35
  16. Thomas E. Clancy · 3 shared papers, 2021–2024 · strength 0.35
  17. Kimmie Ng · 3 shared papers, 2021–2024 · strength 0.35
  18. Michael D. Kluger · 3 shared papers, 2021–2024 · strength 0.35
  19. Kunal Jajoo · 3 shared papers, 2021–2024 · strength 0.35
  20. John A. Chabot · 3 shared papers, 2021–2024 · strength 0.35
  21. Jeanine M. Genkinger · 3 shared papers, 2021–2024 · strength 0.35
  22. Fay Kastrinos · 3 shared papers, 2021–2024 · strength 0.35
  23. Ziding Feng · 2 shared papers, 2020–2026 · strength 0.31
  24. Marta Sans · 2 shared papers, 2023 · strength 0.26
  25. Matthew R. Young · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.